Ischemic Stroke Therapeutics || Secondary Prevention After Ischemic Lacunar Stroke
- 作者Ovbiagele, Bruce
- 文件大小281.86KB
- 发表时间2016
- DOI10.1007/978-3-319-17750-2_13
- 页码137-146
[Methods in Molecular Biology] Gene Therapy for Neurological Disorders Volume 1382 ||Manfredsson, Fredric P. · 2016
The development of flexible lentiviral vectors for gene transfer in the CNSFredric P. Manfredsson; Ronald J. Mandel · 2011
[Methods in Molecular Biology] Gene Therapy for Neurological Disorders Volume 1382 || Regulated Gene TherapyManfredsson, Fredric P. · 2016
[Methods in Molecular Biology] Gene Therapy for Neurological Disorders Volume 1382 || Lentivirus Production and PurificationManfredsson, Fredric P. · 2016
[Methods in Molecular Biology] Gene Therapy for Neurological Disorders Volume 1382 || Viral Vector Production: AdenovirusManfredsson, Fredric P. · 2016
Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesiaSteece‐Collier, Kathy; Stancati, Jennifer A.; Collier, Nicholas J.; Sandoval, Ivette M.; Mercado, Natosha M.; Sortwell, Caryl E.; Collier, Timothy J.; Manfredsson, Fredric P. · Movement Disorders · 2019
Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issuesFredric P. Manfredsson; David C. Bloom; Ronald J. Mandel · 2012
The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's diseaseBenskey, Matthew J.; Perez, Ruth G.; Manfredsson, Fredric P. · Journal of Neurochemistry · 2016